CDEK
← All trials

NCT05505994

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Sep 30, 2022
Primary completion
Mar 31, 2024
Completion date
Aug 31, 2024
First posted
Aug 18, 2022
Last posted
Aug 26, 2022
Enrollment
298
Arms / groups
2 / —
Source
AACT · ctgov ingestion

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.